Literature DB >> 1646319

Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes.

Q Jiang1, A E Takemori, M Sultana, P S Portoghese, W D Bowen, H I Mosberg, F Porreca.   

Abstract

The present study has investigated the direct opioid delta receptor-mediated antinociception produced by i.c.v. administration of the highly selective delta agonists, [D-Pen2,D-Pen5]enkephalin (DPDPE) and [D-Ala2]deltorphin II, as well as that of the less delta-selective [D-Ser2,Leu5,Thr6]enkephalin (DSLET), by using two novel nonequilibrium opioid antagonists, [D-Ala2,Leu5,Cys6] enkephalin (DALCE) and naltrindole 5'-isothiocyanate (5'-NTII). At times ranging from 8 to 48 hr after a single i.c.v. pretreatment of mice with 5'-NTII, the antinociceptive effects of [D-Ala2] deltorphin II were significantly antagonized. In contrast, 5'-NTII pretreatment at times between 10 min and 24 hr failed to antagonize the antinociceptive effects of DPDPE. Previous studies have shown that pretreatment with i.c.v. DALCE produces a dose- and time-related antagonism of DPDPE, but not morphine, antinociception. However, pretreatment with i.c.v. DALCE failed to antagonize the antinociceptive effects of [D-Ala2]deltorphin II. Similarly, i.c.v. administration of DSLET produced time- and dose-related antinociception which was partially antagonized by either beta-funaltrexamine (beta-FNA) or by ICI 174,864 (N,N-dialyl-Tyr-Aib-Aib-Phe-Leu-OH), suggesting mixed activity at mu and delta receptors. ICI 174,864 produced essentially complete antagonism of DSLET antinociception in beta-FNA-pretreated mice. Pretreatment with 5'-NTII (at -8 to -48 hr), blocked the antinociception produced by DSLET in control or in beta-FNA-pretreated mice. In contrast, pretreatment with DALCE failed to antagonize the antinociception produced by i.c.v. DSLET in either control or in beta-FNA-pretreated mice.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646319

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

1.  Supraspinal administration of opioids with selectivity for mu-, delta- and kappa-opioid receptors produces analgesia in amphibians.

Authors:  C W Stevens; K S Rothe
Journal:  Eur J Pharmacol       Date:  1997-07-16       Impact factor: 4.432

Review 2.  Advances in opioid pharmacology.

Authors:  Geoffrey K Gourlay
Journal:  Support Care Cancer       Date:  2004-12-21       Impact factor: 3.603

Review 3.  Molecular recognition of opioid receptor ligands.

Authors:  Brian E Kane; Bengt Svensson; David M Ferguson
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

4.  Activation of delta-opioid receptors reduces excitatory input to putative gustatory cells within the nucleus of the solitary tract.

Authors:  Mingyan Zhu; Young K Cho; Cheng-Shu Li
Journal:  J Neurophysiol       Date:  2008-11-19       Impact factor: 2.714

Review 5.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

6.  Synthesis and pharmacology of halogenated δ-opioid-selective [d-Ala(2)]deltorphin II peptide analogues.

Authors:  Robyn Pescatore; Gina F Marrone; Seth Sedberry; Daniel Vinton; Netanel Finkelstein; Yitzchak E Katlowitz; Gavril W Pasternak; Krista R Wilson; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2015-04-14       Impact factor: 4.418

7.  Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.

Authors:  H Beaudry; L Gendron; J A Morón
Journal:  Eur J Neurosci       Date:  2015-01-09       Impact factor: 3.386

8.  Disruption of morphine-conditioned place preference by a delta2-opioid receptor antagonist: study of mu-opioid and delta-opioid receptor expression at the synapse.

Authors:  Sophie K Billa; Yan Xia; Jose A Morón
Journal:  Eur J Neurosci       Date:  2010-07-09       Impact factor: 3.386

9.  Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay.

Authors:  J H Broadbear; S S Negus; E R Butelman; B R de Costa; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

Review 10.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.